Ulta Beauty Q1 Beats, But Profit and Cash Debates Remain Unresolved

What happened

Ulta Beauty reported double-digit sales and earnings growth in Q1 FY2026, citing broad-based gains, stronger gross margin, and traction in international expansion, marketplace, wellness, and retail media. However, the Master Report's WAIT rating (3.5 conviction) underscores that the stock's 66% rally and premium P/E of 25.5x already price in this momentum, while underlying profit resilience remains contested. Key concerns from Q3 FY2025 persist: SG&A deleveraged to 29.4% of sales, inventories rose to $2.7B, and revolver borrowings hit $552M, leaving operating leverage and cash conversion unproven. The Q1 report did not provide enough detail on whether SG&A is re-leveraging or inventory normalization is on track, keeping the core debates unresolved. At $678, near the top of the Master Report's range, the stock offers limited margin of safety against structural cost pressures and the impending Target partnership unwind.

Implication

The Q1 beat reinforces demand momentum, but the Master Report's concerns about cost creep and cash flow persist. Investors should wait for evidence that SG&A stabilizes below 28.5% of sales and inventory unwinds from $2.7B. Until then, the stock's premium multiple leaves it vulnerable to disappointment. Use dips toward $580 (attractive entry per report) to build positions, but do not chase the rally. The Target partnership unwind in Aug-2026 adds another layer of uncertainty.

Thesis delta

The Q1 headline is positive but does not change the fundamental tension between strong demand and structural cost pressures. The thesis remains WAIT until SG&A re-leverage and cash conversion are confirmed.